Showing 21 - 40 results of 48 for search '"Norwegian Institute of Public Health"', query time: 0.06s Refine Results
  1. 21
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37
  18. 38

    Association Between GABRG2 and Self-Rating of the Effects of Alcohol in a French Young Adult Sample by Moe JS, Bramness JG, Bolstad I, Mørland JG, Gorwood P, Ramoz N

    Published 2025-01-01
    “…Jenny Skumsnes Moe,1,2 Jørgen G Bramness,1– 4 Ingeborg Bolstad,1,5 Jørg Gustav Mørland,3,6 Philip Gorwood,7,8 Nicolas Ramoz7,8 1Research Center for Substance Use Disorders and Mental Illness, Innlandet Hospital Trust, Brumunddal, Norway; 2Institute for Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; 3Department of Alcohol, Tobacco, and Drugs, Norwegian Institute of Public Health, Oslo, Norway; 4Section for Clinical Addiction Research, Oslo University Hospital, Oslo, Norway; 5Department of Health and Social Science, Inland Norway University of Applied Sciences, Elverum, Norway; 6Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 7Université Paris Cité, Inserm U1266, Institut de Psychiatrie et Neurosciences de Paris (IPNP), Team Vulnerability of Psychiatric and Addictive Disorders, Paris, France; 8GHU PARIS Psychiatrie & Neurosciences, Hôpital Sainte-Anne, CMME, Paris, FranceCorrespondence: Jenny Skumsnes Moe, Research Center for Substance Use Disorders and Mental Illness, Innlandet Hospital Trust, P.O. …”
    Get full text
    Article
  19. 39
  20. 40

    Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data St... by Puco K, Notland CS, Szulkin R, Jonasson C, Beisland C, Johannesen TB, Solli O, Oldenburg J, Heinrich D

    Published 2025-01-01
    “…Katarina Puco,1 Cathrine S Notland,2 Robert Szulkin,3,4 Christian Jonasson,5 Christian Beisland,6,7 Tom B Johannesen,8 Oddvar Solli,9 Jan Oldenburg,10,11 Daniel Heinrich12 1Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway; 2Department of Medical Affairs, Pfizer AS, Oslo, Norway; 3SDS Life Science, Stockholm, Sweden; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden; 5Department of Public Health and Nursing, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 6Department of Urology, Haukeland University Hospital, Bergen, Norway; 7Department of Clinical Medicine, University of Bergen, Bergen, Norway; 8Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; 9Health and Value, Pfizer AS, Oslo, Norway; 10Department of Oncology, Akershus University Hospital HF, Lørenskog, Norway; 11Faculty of Medicine, University of Oslo, Oslo, Norway; 12Department of Radiotherapy and Oncology, Innlandet Hospital Trust HF, Division Gjøvik/Lillehammer, NorwayCorrespondence: Katarina Puco, Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway, Tel +47  416 86 298, Email katarina.puco@lds.noPurpose: In Norway, 5-year survival rates of patients with renal cell carcinoma (RCC) are increasing. …”
    Get full text
    Article